RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells Corrigendum in /10.3892/ol.2022.13211

Liu,Tao; Liao,Yixiang; Tao,Huangheng; Zeng,Jinmin; Wang,Gang; Yang,Zhonghua; Wang,Yongzhi; Xiao,Yu; Zhou,Jiajie; Wang,Xinghuan

doi:10.3892/ol.2018.7847

RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells

Corrigendum in: /10.3892/ol.2022.13211

Authors:
- Tao Liu
- Yixiang Liao
- Huangheng Tao
- Jinmin Zeng
- Gang Wang
- Zhonghua Yang
- Yongzhi Wang
- Yu Xiao
- Jiajie Zhou
- Xinghuan Wang
View Affiliations

Affiliations: Department of Urology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei 434020, P.R. China, Key Laboratory for Oral Biomedicine of Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Urology, Center for Medical Science Research, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: January 24, 2018 https://doi.org/10.3892/ol.2018.7847
Pages: 4129-4136
Copyright : © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several studies have shown that transient receptor potential cation channel subfamily M member 8 (TRPM8), which has been regarded as a novel prostate‑specific marker, serves a key role in processes such as the proliferation, viability and cell migration of prostate cancer cells. Efforts have been made to uncover the potential role of targeting TRPM8 in the management of prostate cancer; it has been verified that TRPM8‑targeted blockade, either by RNA interference-mediated depletion or specific TRPM8 inhibitors, could reduce the rate of proliferation and proliferative fraction, and induce apoptosis in prostate cancer cells. The aim of the present study was to investigate the effect of knockdown of TRPM8 on chemosensitivity in prostate cancer LNCaP and PC3 cells. The RNA interference‑mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen‑activated protein kinase (hereafter p38) and c‑Jun N‑terminal kinase (JNK)/mitogen‑activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK. The results demonstrate that the targeted silencing of TRPM8 expression is a therapeutic strategy for treatment of prostate cancer that has considerable potential, even for castration‑resistant prostate cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zhang L and Barritt GJ: Evidence that TRPM8 is an androgen-dependent Ca₂+ channel required for the survival of prostate cancer cells. Cancer Res. 64:8365–8373. 2004. View Article : Google Scholar : PubMed/NCBI
3	Egan A, Dong Y, Zhang H, Qi Y, Balk SP and Sartor O: Castration-resistant prostate cancer: Adaptive responses in the androgen axis. Cancer Treat Rev. 40:426–433. 2014. View Article : Google Scholar : PubMed/NCBI
4	Katzenwadel A and Wolf P: Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. Cancer Lett. 367:12–17. 2015. View Article : Google Scholar : PubMed/NCBI
5	Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Barbanti G, Bianco V, Brozzetti S and Francini E: Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: A single-institution experience. Med Oncol. 32:522015. View Article : Google Scholar : PubMed/NCBI
6	Thebault S, Flourakis M, Vanoverberghe K, Vandermoere F, Roudbaraki M, Lehen'kyi V, Slomianny C, Beck B, Mariot P, Bonnal JL, et al: Differential role of transient receptor potential channels in Ca²⁺ entry and proliferation of prostate cancer epithelial cells. Cancer Res. 66:2038–2047. 2006. View Article : Google Scholar : PubMed/NCBI
7	Yee NS: Roles of TRPM8 ion channels in cancer: Proliferation, survival and invasion. Cancers (Basel). 7:2134–2146. 2015. View Article : Google Scholar : PubMed/NCBI
8	Grolez GP and Gkika D: TRPM8 puts the chill on prostate cancer. Pharmaceuticals (Basel). 9:E442016. View Article : Google Scholar : PubMed/NCBI
9	Flourakis M and Prevarskaya N: Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta. 1793:1105–1109. 2009. View Article : Google Scholar : PubMed/NCBI
10	Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, Skryma R and Prevarskaya N: Ca²⁺ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ. 11:321–330. 2004. View Article : Google Scholar : PubMed/NCBI
11	Skryma R, Mariot P, Bourhis XL, Coppenolle FV, Shuba Y, Vanden Abeele F, Legrand G, Humez S, Boilly B and Prevarskaya N: Store depletion and store-operated Ca²⁺ current in human prostate cancer LNCaP cells: Involvement in apoptosis. J Physiol. 527:71–83. 2000. View Article : Google Scholar : PubMed/NCBI
12	Vanden AF, Roudbaraki M, Shuba Y, Skryma R and Prevarskaya N: Store-operated Ca²⁺ current in prostate cancer epithelial cells. Role of endogenous Ca²⁺ transporter type 1. J Biol Chem. 278:15381–15389. 2003. View Article : Google Scholar : PubMed/NCBI
13	Yu S, Xu Z, Zou C, Wu D, Wang Y, Yao X, Ng CF and Chan FL: Ion channel TRPM8 promotes hypoxic growth of prostate cancer cells via an O2-independent and RACK1-mediated mechanism of HIF-1α stabilization. J Pathol. 234:514–525. 2014. View Article : Google Scholar : PubMed/NCBI
14	Peng M, Wang Z, Yang Z, Tao L, Liu Q, Yi LU and Wang X: Overexpression of short TRPM8 variant alpha promotes cell migration and invasion and decreases starvation-induced apoptosis in prostate cancer LNCaP cells. Oncol Lett. 10:1378–1384. 2015. View Article : Google Scholar : PubMed/NCBI
15	Bidaux G, Borowiec AS, Dubois C, Delcourt P, Schulz C, Vanden Abeele F, Lepage G, Desruelles E, Bokhobza A, Dewailly E, et al: Targeting of short TRPM8 isoforms induces 4TM-TRPM8-dependent apoptosis in prostate cancer cells. Oncotarget. 7:29063–29080. 2016. View Article : Google Scholar : PubMed/NCBI
16	Asuthkar S, Velpula KK, Elustondo PA, Demirkhanyan L and Zakharian E: TRPM8 channel as a novel molecular target in androgen-regulated prostate cancer cells. Oncotarget. 6:17221–17236. 2015. View Article : Google Scholar : PubMed/NCBI
17	Valero ML, Mello de Queiroz F, Stühmer W, Viana F and Pardo LA: TRPM8 ion channels differentially modulate proliferation and cell cycle distribution of normal and cancer prostate cells. PLoS One. 7:e518252012. View Article : Google Scholar : PubMed/NCBI
18	Grolez GP and Gkika D: TRPM8 puts the chill on prostate cancer. Pharmaceuticals (Basel). 9:E442016. View Article : Google Scholar : PubMed/NCBI
19	Zhu G, Wang X, Yang Z, Cao H, Meng Z, Wang Y and Chen D: Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo. Oncol Lett. 2:1213–1217. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yang ZH, Wang XH, Wang HP and Hu LQ: Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl. 11:157–165. 2009. View Article : Google Scholar : PubMed/NCBI
21	Peng M, Wang Z, Yang Z, Tao L, Liu Q, Yi LU and Wang X: Overexpression of short TRPM8 variant α promotes cell migration and invasion and decreases starvation-induced apoptosis in prostate cancer LNCaP cells. Oncol Lett. 10:1378–1384. 2015. View Article : Google Scholar : PubMed/NCBI
22	Valero M, Morenilla-Palao C, Belmonte C and Viana F: Pharmacological and functional properties of TRPM8 channels in prostate tumor cells. Pflugers Arch. 461:99–114. 2011. View Article : Google Scholar : PubMed/NCBI
23	Liu T, Fang Z, Wang G, Shi M, Wang X, Jiang K, Yang Z, Cao R, Tao H, Wang X and Zhou J: Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 11:182–188. 2016. View Article : Google Scholar : PubMed/NCBI
24	Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G and Barbanti G: Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: A randomised phase II study. Br J Cancer. 104:613–619. 2011. View Article : Google Scholar : PubMed/NCBI
25	Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, et al: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 63:4196–4203. 2003.PubMed/NCBI
26	Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, et al: Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. J Clin Invest. 117:1647–1657. 2007. View Article : Google Scholar : PubMed/NCBI
27	Thebault S, Lemonnier L, Bidaux G, Flourakis M, Bavencoffe A, Gordienko D, Roudbaraki M, Delcourt P, Panchin Y, Shuba Y, et al: Novel role of cold/menthol-sensitive transient receptor potential melastatine family member 8 (TRPM8) in the activation of store-operated channels in LNCaP human prostate cancer epithelial cells. J Biol Chem. 280:39423–39435. 2005. View Article : Google Scholar : PubMed/NCBI
28	Kim SH, Nam JH, Park EJ, Kim BJ, Kim SJ, So I and Jeon JH: Menthol regulates TRPM8-independent processes in PC-3 prostate cancer cells. Biochim Biophys Acta. 1792:33–38. 2009. View Article : Google Scholar : PubMed/NCBI